



Cancer and Hematology Center Clinical Trials



As a recognized leader in clinical, translational and laboratory research, we offer clinical trials for a wide range of children's cancer and blood disorders.



See back for a list of featured trials. These are also available on our website by scanning the QR code or visiting texaschildrens.org/ClinTrials

To learn more about the Center, visit texaschildrens.org/cancer



Texas Children's
Hospital®

Featured clinical trials 2026

Solid Tumors

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination with Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (ONITT)

Brain Tumors

C7R-GD2.CAR T Cells for Patients with GD2-expressing Brain Tumors (GAIL-B)

Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study

HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children with Ependymoma (PBTC-059)

Leukemia/Lymphoma

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

A Study to find the Highest Dose of Imetelstat in Combination with Fludarabine and Cytarabine for Patients with AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (PEPN2312)

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

EBV Specific T Lymphocytes for Treatment of EBV-Positive Lymphoma (CILESTE)

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas (CABAL2)

Allogeneic CD30.CAR-EBVSTS in Patients with Relapsed or Refractory CD30-Positive Lymphomas

Cell and Gene Therapy

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells (CRIMSON)

TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT (TETRAVI)

TAZNI: A Phase I/II Combination Trial of Tazemetostat With Nivolumab and Ipilimumab for Children With INI1-Negative or SMARCA4-Deficient Tumors

UPDATE AML: A New Chemotherapy Approach for Pediatric Acute Myeloid Leukemia

Histiocytic Diseases

Vinblastine/Prednisone versus Single Therapy with Cytarabine for Langerhans Cell Histiocytosis (LCH)

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders (NACHO COBI)

TCH Histiocytosis Biology Study (H-25667)

NACHO-BIO: Biology Study for Histiocytic Disorders

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Open-label Study of ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Blood, Immune and Vascular Disorders

A Phase 2 Study of Mutant-selective PI3K α Inhibitor, RLY-2608, to treat PIK3CA Related Overgrowth Spectrum (PROS) and Malformations Driven by PIK3CA Mutation

A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations (SELVA)

Alpelisib in Pediatric and Adult Patients with Lymphatic Malformations Associated with a PIK3CA Mutation (EPIK-L1)

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (EPIK-P2)

